Sarat Chandarlapaty

Sarat Chandarlapaty

UNVERIFIED PROFILE

Are you Sarat Chandarlapaty?   Register this Author

Register author
Sarat Chandarlapaty

Sarat Chandarlapaty

Publications by authors named "Sarat Chandarlapaty"

Are you Sarat Chandarlapaty?   Register this Author

65Publications

1918Reads

8Profile Views

Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.

J Med Chem 2019 Aug 2;62(16):7575-7582. Epub 2019 Aug 2.

MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology , Tsinghua University , Beijing 100084 , P. R. China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.9b00871DOI Listing
August 2019

Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors.

J Clin Oncol 2019 May 28;37(14):1148-1150. Epub 2019 Mar 28.

1 Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.00090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506417PMC
May 2019

Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer.

Cancer Discov 2019 Mar;9(3):323-325

Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-0050DOI Listing
March 2019

Reversible histone glycation is associated with disease-related changes in chromatin architecture.

Nat Commun 2019 03 20;10(1):1289. Epub 2019 Mar 20.

Chemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-09192-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426841PMC
March 2019

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Cancer Cell 2018 12;34(6):893-905.e8

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA; Breast Medicine Service, Department of Medicine, MSKCC, New York, NY 10065, USA; Weill-Cornell Medical College, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183052
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294301PMC
December 2018

Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Cancer Cell 2018 11 1;34(5):852-862.e4. Epub 2018 Nov 1.

Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.10.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234065PMC
November 2018

Publisher Correction: Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.

Nat Rev Cancer 2018 Oct;18(10):662

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41568-018-0053-0DOI Listing
October 2018

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(26):2736-2740. Epub 2018 Jun 25.

Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Ian E. Krop, Nancy U. Lin, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jennifer Levinson, Ponte Vedra Beach; Naren Ramakrishna, Orlando Health University of Florida Health Cancer Center, Orlando, FL; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2697DOI Listing
September 2018

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(27):2804-2807. Epub 2018 Jun 25.

Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Sharon H. Giordano, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Ian E. Krop, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2713DOI Listing
September 2018

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.

Oncogene 2018 08 14;37(34):4692-4710. Epub 2018 May 14.

Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-018-0273-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107480PMC
August 2018

New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.

ACS Med Chem Lett 2018 Aug 5;9(8):803-808. Epub 2018 Jul 5.

Department of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, New Jersey 07601 United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.8b00106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088359PMC
August 2018

Incorporating Biology Into Breast Cancer Staging: American Joint Committee on Cancer, Eighth Edition, Revisions and Beyond.

Am Soc Clin Oncol Educ Book 2018 May;38:38-46

From the Dana-Farber Cancer Institute and Brigham and Women's Cancer Center, Boston, MA; Ontario Institute for Cancer Research, Ontario, Canada; Cancer Prevention Institute of California, Fremont, CA; Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200981DOI Listing
May 2018

AKT Inhibition in Solid Tumors With AKT1 Mutations.

J Clin Oncol 2017 Jul 10;35(20):2251-2259. Epub 2017 May 10.

David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue, Matthew T. Chang, Jonathan B. Reichel, Nancy Bouvier, S. Duygu Selcuklu, Tara E. Soumerai, Jean Torrisi, Joseph P. Erinjeri, Michael F. Berger, Sarat Chandarlapaty, David B. Solit, José Baselga, and Barry S. Taylor, Memorial Sloan Kettering Cancer Center; David B. Solit, Weill Cornell Medical College, Cornell University, New York, NY; J. Carl Barrett and Brian Dougherty, AstraZeneca, Waltham, MA; Helen Ambrose, Andrew Foxley, Justin P.O. Lindemann, Robert McEwen, Martin Pass, and Gaia Schiavon, AstraZeneca, Cambridge; Emma J. Dean, The Christie National Health Service Foundation, Manchester; Udai Banerji, Royal Marsden Hospital, London, United Kingdom; Shannon N. Westin, The University of Texas MD Anderson Cancer Center, Houston, TX; Philippe L. Bedard, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Hideaki Bando, National Cancer Center East Hospital, Kashiwa, Japan; Anthony B. El-Khoueiry, University of Southern California Norris Comprehensive Cancer Center; Alain Mita, Cedars-Sinai Medical Center, Los Angeles, CA; José A. Pérez-Fidalgo, Hospital Clinico de Valencia, Valencia, Spain; and Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.0143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501365PMC
July 2017

OncoKB: A Precision Oncology Knowledge Base.

JCO Precis Oncol 2017 Jul 16;2017. Epub 2017 May 16.

, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , , Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Department of R&D and Bioinformatics, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://www.researchgate.net/profile/Debyani_Chakravarty/pub
Web Search
http://ascopubs.org/doi/10.1200/PO.17.00011
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586540PMC
http://dx.doi.org/10.1200/PO.17.00011DOI Listing
July 2017

Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.

J Nucl Med 2016 Oct 5;57(10):1523-1528. Epub 2016 May 5.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York Department of Radiology, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050126PMC
http://dx.doi.org/10.2967/jnumed.115.172031DOI Listing
October 2016

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.

Cancer Cell 2016 08 21;30(2):229-242. Epub 2016 Jul 21.

Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982440PMC
August 2016

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Sci Transl Med 2015 Apr;7(283):283ra51

Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaa4442DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433148PMC
April 2015

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Cancer Cell 2015 Jan 24;27(1):109-22. Epub 2014 Dec 24.

Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2014.11.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293347PMC
January 2015

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

J Clin Oncol 2014 Jul 5;32(19):2078-99. Epub 2014 May 5.

Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Cancer Institute, New York, NY; Jennie R. Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Ian Krop, Nancy U. Lin, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jennifer Levinson, Ponte Vedra Beach; Edith A. Perez, Mayo Clinic, Jacksonville; Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.0948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076031PMC
July 2014

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

J Clin Oncol 2014 Jul 5;32(19):2100-8. Epub 2014 May 5.

Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Edith A. Perez, Mayo Clinic, Jacksonville; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Cancer Institute, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Ian Krop, Eric P. Winter, and Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/32/19/2100.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.0955
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.0955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366342PMC
July 2014

PTEN is a protein tyrosine phosphatase for IRS1.

Nat Struct Mol Biol 2014 Jun 11;21(6):522-7. Epub 2014 May 11.

Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nsmb.2828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167033PMC
June 2014

PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.

Clin Cancer Res 2014 May 14;20(9):2326-37. Epub 2014 Mar 14.

Authors' Affiliations: Breast Service, Department of Surgery; Departments of Pathology; and Medicine; and the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015460PMC
May 2014

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Cancer Discov 2014 Mar 16;4(3):334-47. Epub 2014 Jan 16.

1Program in Molecular Pharmacology; 2Human Oncology and Pathogenesis Program; 3Program in Cell Biology, Memorial Sloan-Kettering Cancer Center; 4Weill Cornell Medical College, New York, New York; and 5Bayer HealthCare, Global Drug Discovery, Berlin, Germany.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-13-0611DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049524PMC
March 2014

Molecular pathways: HER3 targeted therapy.

Clin Cancer Res 2014 Mar 11;20(6):1410-6. Epub 2014 Feb 11.

Authors' Affiliations: Gerstner Sloan Kettering Graduate School of Biomedical Sciences; and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1549DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977203PMC
March 2014

Negative feedback and adaptive resistance to the targeted therapy of cancer.

Cancer Discov 2012 Apr 22;2(4):311-9. Epub 2012 Mar 22.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-12-0018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351275PMC
April 2012

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Cancer Discov 2011 Aug 17;1(3):248-59. Epub 2011 Jun 17.

Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-11-0085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227125PMC
August 2011

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

Expert Rev Anticancer Ther 2011 Feb;11(2):263-75

Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 300 E 66th Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/era.10.226
Publisher Site
http://dx.doi.org/10.1586/era.10.226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092522PMC
February 2011

Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.

Appl Immunohistochem Mol Morphol 2010 Jul;18(4):371-4

Sloan-Kettering Institute, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0b013e3181d50bd5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921801PMC
July 2010

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

PLoS One 2008 Aug 26;3(8):e3065. Epub 2008 Aug 26.

Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0003065PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2516933PMC
August 2008